Page last updated: 2024-11-07

2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin F1alpha: formed from 6-keto-PGF1alpha by Mycobacterium rhodochrous; RN given refers to (1R-(1alpha,2beta,3alpha,5alpha))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155031
MeSH IDM0091202

Synonyms (11)

Synonym
2,3-dinor-6,15-dioxo-13,14-dihydroprostaglandin f1alpha
5-[(1s,2s,3s,5r)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]-4-oxopentanoic acid
2,3-dinor-6,15-diketo-13,14-dihydro-pgf1alpha
2,3-dddpgf1alpha
2,3-dinor-6,15-diketo-pgf1alpha
2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha
2,3-dinor-6,15-dioxo-13,14-dihydro-pgf1alpha
68376-88-5
cyclopentanepentanoic acid, 3,5-dihydroxy-gamma-oxo-2-(3-oxooctyl)-, (1s-(1alpha,2beta,3alpha,5alpha))-
5-[3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]-4-oxopentanoic acid
DTXSID40987922

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Serum thromboxane B2 and aggregation studies in whole blood and platelet-rich plasma were measured before dosing and at 1, 4, 6, 8, and 24 h after dosing."( Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
Brash, AR; FitzGerald, GA; Oates, JA; Pedersen, AK, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]